Literature DB >> 24155898

Angiotensin II facilitates fibrogenic effect of TGF-β1 through enhancing the down-regulation of BAMBI caused by LPS: a new pro-fibrotic mechanism of angiotensin II.

Yu-Sheng Li1, Shu-Yuan Ni, Ying Meng, Xiao-Lan Shi, Xu-Wen Zhao, Hai-Hua Luo, Xu Li.   

Abstract

Angiotensin II has progressively been considered to play an important role in the development of liver fibrosis, although the mechanism isn't fully understood. The aim of this study was to investigate a possible pro-fibrotic mechanism, by which angiotensin II would enhance the pro-fibrotic effect of transforming growth factor beta 1 (TGF-β1) through up-regulation of toll-like receptor 4 (TLR4) and enhancing down-regulation of TGF-β1 inhibitory pseudo-receptor-BAMBI caused by LPS in hepatic stellate cells (HSCs). Firstly, the synergistic effects of angiotensin II, TGF-β1 and LPS on collagen 1α production were confirmed in vitro by ELISA, in which angiotensin II, LPS and TGF-β1 were treated sequentially, and in vivo by immunofluorescence, in the experiments single or multiple intra-peritoneally implanted osmotic mini-pumps administrating angiotensin II or LPS combined with intra-peritoneal injections of TGF-β1 were used. We also found that only LPS and TGF-β1 weren't enough to induce obvious fibrogenesis without angiotensin II. Secondly, to identify the reason of why angiotensin II is so important, the minute level of TLR4 in activated HSCs - T6 and primary quiescent HSCs of rat, up-regulation of TLR4 by angiotensin II and blockage by different angiotensin II receptor type 1 (AT1) blockers in HSCs were assayed by western blotting in vitro and immunofluorescence in vivo. Finally, BAMBI expression level, which is regulated by LPS-TLR4 pathway, was detected by qRT-PCR and results showed angiotensin II enhanced the down-regulation of BAMBI mRNA caused by LPS in vitro and in vivo, and TLR4 neutralization antibody blocked this interactive effect. These data demonstrated that angiotensin II enhances LPS-TLR4 pathway signaling and further down-regulates expression of BAMBI through up-regulation of TLR4, which results in facilitation of pro-fibrotic activity of TGF-β1. Angiotensin II, LPS and TGF-β1 act synergistically during hepatic fibrogenesis, showing crosstalks between angiotensin II-AT1, LPS-TLR4 and TGF-β1-BAMBI signal pathways in rat HSCs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24155898      PMCID: PMC3796560          DOI: 10.1371/journal.pone.0076289

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  45 in total

Review 1.  Anti-fibrogenic strategies and the regression of fibrosis.

Authors:  Tatiana Kisseleva; David A Brenner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

Review 2.  Platelet-derived growth factor.

Authors:  R Ross
Journal:  Lancet       Date:  1989-05-27       Impact factor: 79.321

3.  Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis.

Authors:  M Pinzani; S Milani; H Herbst; R DeFranco; C Grappone; A Gentilini; A Caligiuri; G Pellegrini; D V Ngo; R G Romanelli; P Gentilini
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

4.  A cardioprotective role for the endothelial protein C receptor in lipopolysaccharide-induced endotoxemia in the mouse.

Authors:  Takayuki Iwaki; Diana T Cruz; J Andrew Martin; Francis J Castellino
Journal:  Blood       Date:  2004-11-04       Impact factor: 22.113

5.  Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells.

Authors:  M Pinzani; L Gesualdo; G M Sabbah; H E Abboud
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

6.  Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells.

Authors:  Yong-Han Paik; Robert F Schwabe; Ramón Bataller; Maria P Russo; Christian Jobin; David A Brenner
Journal:  Hepatology       Date:  2003-05       Impact factor: 17.425

7.  Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice.

Authors:  Piotr Czochra; Borut Klopcic; Erik Meyer; Johannes Herkel; Jose Francisco Garcia-Lazaro; Florian Thieringer; Peter Schirmacher; Stefan Biesterfeld; Peter R Galle; Ansgar W Lohse; Stephan Kanzler
Journal:  J Hepatol       Date:  2006-05-30       Impact factor: 25.083

8.  Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions.

Authors:  N Sanderson; V Factor; P Nagy; J Kopp; P Kondaiah; L Wakefield; A B Roberts; M B Sporn; S S Thorgeirsson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

9.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

10.  Differential regulation of Toll-like receptor 4 gene expression in renal cells by angiotensin II: dependency on AP1 and PU.1 transcriptional sites.

Authors:  Tzvetanka Bondeva; Thierry Roger; Gunter Wolf
Journal:  Am J Nephrol       Date:  2007-05-08       Impact factor: 3.754

View more
  14 in total

Review 1.  Targeting Hepatic Fibrosis in Autoimmune Hepatitis.

Authors:  Aldo J Montano-Loza; Ragesh B Thandassery; Albert J Czaja
Journal:  Dig Dis Sci       Date:  2016-07-19       Impact factor: 3.199

2.  Valsartan ameliorates high glucose-induced peritoneal fibrosis by blocking mTORC1 signaling.

Authors:  Jing Liu; Yuan Feng; Cheng Sun; Wei Zhu; Qing-Yan Zhang; Bo Jin; Qiu-Yuan Shao; Yang-Yang Xia; Peng-Fei Xu; Miao Zhang; Chun-Ming Jiang
Journal:  Exp Biol Med (Maywood)       Date:  2020-05-14

Review 3.  Periostin in intrahepatic cholangiocarcinoma: pathobiological insights and clinical implications.

Authors:  Alphonse E Sirica; Jorge A Almenara; Chao Li
Journal:  Exp Mol Pathol       Date:  2014-10-28       Impact factor: 3.362

Review 4.  Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update.

Authors:  Gülsüm Özlem Elpek
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

5.  Urantide improves atherosclerosis by controlling C-reactive protein, monocyte chemotactic protein-1 and transforming growth factor-β expression in rats.

Authors:  Juan Zhao; Li-DE Xie; Cheng-Jun Song; Xiao-Xia Mao; Hai-Rong Yu; Quan-Xin Yu; Li-Qun Ren; Yan Shi; Ya-Qin Xie; Ying Li; Sha-Sha Liu; Xiao-Hong Yang
Journal:  Exp Ther Med       Date:  2014-03-31       Impact factor: 2.447

6.  The Cooperative Effect of Local Angiotensin-II in Liver with Adriamycin Hepatotoxicity on Mitochondria.

Authors:  Eylem Taskin; Celal Guven; Leyla Sahin; Nurcan Dursun
Journal:  Med Sci Monit       Date:  2016-03-28

7.  Current and emerging pharmacological therapy for non-alcoholic fatty liver disease.

Authors:  Ahad Eshraghian
Journal:  World J Gastroenterol       Date:  2017-11-14       Impact factor: 5.742

Review 8.  Antifibrotics in liver disease: are we getting closer to clinical use?

Authors:  Meena B Bansal; Naichaya Chamroonkul
Journal:  Hepatol Int       Date:  2018-10-09       Impact factor: 6.047

9.  Angiotensin-II activates vascular inflammasome and induces vascular damage.

Authors:  Stefany B Cau; Ariane Bruder-Nascimento; Marcondes B Silva; Fernanda N Z Ramalho; Fabiola Mestriner; Rheure Alves-Lopes; Nathanne Ferreira; Rita C Tostes; Thiago Bruder-Nascimento
Journal:  Vascul Pharmacol       Date:  2021-06-09       Impact factor: 5.738

10.  TGF-β/BAMBI pathway dysfunction contributes to peripheral Th17/Treg imbalance in chronic obstructive pulmonary disease.

Authors:  Jian-Chu Zhang; Gang Chen; Long Chen; Zhao-Ji Meng; Xian-Zhi Xiong; Hong-Ju Liu; Yang Jin; Xiao-Nan Tao; Jiang-Hua Wu; Sheng-Wen Sun
Journal:  Sci Rep       Date:  2016-08-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.